Case Work

A Poland-based AI diagnostics company with established deployments in Eastern European hospitals approached Medora with the intention to expand into Germany. The product demonstrated strong clinical performance and was already integrated into hospital radiology workflows. The leadership team assumed that this traction would translate into rapid adoption in Germany.

The product itself was technically strong and clinically validated, yet early conversations with German providers repeatedly stalled. This created a clear example of a situation where success in one system created false confidence when entering a structurally different one.

From first conversation to first tangible results: five weeks. This included initial diagnosis, product adaptation definition, and re-engagement with target providers.

Founder and CEO, Head of Product, clinical advisor from the company side. On the Medora side, direct involvement at principal level with targeted input from regulatory and clinical workflow specialists when required.

The work began with a structured diagnosis of where the product failed to align with German diagnostic workflows.

This included reviewing how radiology decisions are made in Praxis and MVZ environments compared to hospital settings. The value proposition was then redefined to reflect how German providers evaluate efficiency and clinical benefit. Product gaps were identified, not at the level of core technology, but at the level of usability, integration expectations, and reporting structure. A revised entry strategy was developed, focusing on specific provider segments rather than broad hospital outreach.

A Romanian digital therapeutics company aimed to enter the German market through the DiGA reimbursement pathway. The product had clinical backing and demonstrated patient engagement in its home market, but the team lacked experience with German regulatory and reimbursement expectations.

The company approached Germany with a clear strategy, but underestimated how specific and demanding the DiGA pathway is. This created a situation where the product appeared ready on the surface, while critical gaps existed beneath.

Six weeks from initial assessment to a structured DiGA readiness roadmap with defined next steps.

CEO, Chief Medical Officer, Head of Product. External clinical advisors were involved on the client side. Medora worked directly with leadership and product teams, with additional input on regulatory interpretation where necessary.

The engagement started with a detailed assessment of the product against DiGA requirements.

This included clinical evidence, usability, and data handling. Gaps were identified in both the evidence structure and patient interaction design. The onboarding and engagement flows were reworked to better match expectations of German patients and evaluators. Positioning was refined to differentiate the product from existing DiGA solutions, with a clear articulation of its clinical and economic value.

An Estonian remote care platform with strong traction in Nordic markets aimed to expand into Germany. The product was designed around a centralized care model and assumed similar adoption dynamics in the German system.

The company had already succeeded in multiple markets and approached Germany with confidence. The case illustrates how prior success can obscure structural differences and delay recognition of fundamental misalignment.

Five weeks from initial conversation to securing the first pilot agreement with a German provider.

CEO, Head of Growth, Product Lead. On the Medora side, direct involvement with strategic and product adaptation work, supported by targeted input on provider landscape.

The initial phase focused on identifying why the existing value proposition did not resonate with German stakeholders.

The product was reframed to address specific pain points within fragmented care delivery. Target segments were narrowed down to those most likely to adopt early. A structured pilot strategy was developed, including partner identification and engagement approach. Messaging was adapted to reflect how German providers evaluate new solutions.